Cas:916909-01-8 2-phenyl-6-(trifluoromethyl)-4,5-dihydropyridazin-3-one manufacturer & supplier

We serve Chemical Name:2-phenyl-6-(trifluoromethyl)-4,5-dihydropyridazin-3-one CAS:916909-01-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-phenyl-6-(trifluoromethyl)-4,5-dihydropyridazin-3-one

Chemical Name:2-phenyl-6-(trifluoromethyl)-4,5-dihydropyridazin-3-one
CAS.NO:916909-01-8
Synonyms:2-phenyl-6-(trifluoromethyl)-4,5-dihydropyridazin-3-one
Molecular Formula:C11H9F3N2O
Molecular Weight:242.19700
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:32.67000
Exact Mass:242.06700
LogP:2.23230

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-phenyl-6-(trifluoromethyl)-4,5-dihydropyridazin-3-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-phenyl-6-(trifluoromethyl)-4,5-dihydropyridazin-3-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-phenyl-6-(trifluoromethyl)-4,5-dihydropyridazin-3-one Use and application,2-phenyl-6-(trifluoromethyl)-4,5-dihydropyridazin-3-one technical grade,usp/ep/jp grade.


Related News: The jury unanimously ruled in Plexxikon’s favor on all seven questions, including that Novartis has not proved the specification of the patent was full and clear enough to enable a person of “ordinary skill” to make and use the invention. FMoc-L-4-(OtButylcarboxyMethyl)phe-OH manufacturers After examining all the evidence, it was clear that more plausible explanations for the AML cases included the conditioning treatment the patients received to clear out bone marrow cells and the higher risk of blood cancer in people with sickle cell disease. Methyl 5-chloro-2-cyanobenzoate suppliers As the Covid-19 pandemic continues to challenge the global drug supply chain, nations are looking for new ways to enable native producers to continue scaling up. Now, an Israeli API maker is dropping a down payment into an Indian intermediates company to ramp up its own manufacturing base. 1,4-dimethyl-2,3-dihydroquinoxaline-6-carboxylic acid vendor & factory.